search
metabolism drugs
Trends
- 1Inventiva Reports Unaudited First-Half 2026 Results and Corporate Update▼Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
French biopharmaceutical company Inventiva has published unaudited financial results for the first half of 2026, alongside a corporate update on its business. The company, known for developing treatments for metabolic diseases such as NASH, released the figures through standard financial news channels. Details on revenue, cash position and pipeline progress were included in the announcement.